Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey
Adoption of Leqembi is even slower than expected. EXTON, PA., February 22, 2024 — The 2023 announcement of newly approved disease-modifying therapy (DMT) Leqembi (lecanemab) for Alzheimer’s Disease (AD) sparked eager anticipation within both the medical community and among families nationwide. The debut of Aduhelm from Biogen in 2021 brought with it a wave of […]
Parkinson’s Disease Patient Identification and Education Will Need to Improve When New Disease Modifying Therapies Are Approved, According to Spherix Global Insights
Earlier screening will be needed in the age of biomarkers. EXTON, PA., February 16, 2024 — Millions of people worldwide are affected by Parkinson’s disease (PD), prompting the need for effective disease-modifying therapies (DMTs) to target this degenerative condition. With gene therapies emerging as an exciting potential mechanism of action (MOA) for future treatment, their […]
Potential for new Huntington’s treatment sparks optimism for MDs
But US neurologists also express frustration with current lack of therapies Neurologists in the U.S. are optimistic about the potential for a new treatment for Huntington’s disease, but emphasize the need for therapies that halt nerve degeneration before symptom onset, according to a report by Spherix Global Insights. Most of the specialist physicians surveyed hoped for a […]
US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority
According to Spherix Global Insights’ first market landscape study on Huntington’s disease, neurologists are staking their hopes on gene therapy. EXTON, Pa., January 3, 2024 – Huntington’s disease (HD) could be called the perfect storm of neurodegenerative diseases. It causes a loss of critical striatal neurons which affect not only motor function – causing symptoms […]
US neurologists favorably view BTK inhibitors as potential MS therapies
But Spherix surveys across 2023 may not reflect recent setbacks in clinical trials More than one-third of neurologists in the U.S. believe Bruton’s tyrosine kinase (BTK) inhibitors could be of pivotal significance as a future treatment of multiple sclerosis (MS), according to findings of a recent Spherix Global Insights’ survey. “Through Spherix’s quarterly RealTime Dynamix market tracker, neurologists and […]
U.S. Neurologists Eagerly Await Promising Oral Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis Treatment Pipeline, Though Recent Trial Readouts Might Hamper Initial Excitement
Efficacy and safety of pipeline multiple sclerosis assets viewed as increasingly important characteristics, according to Spherix Global Insights. [Exton PA, December 13, 2023] — Several clinical trials are underway for Bruton’s tyrosine kinase inhibitors (BTKi) targeting relapsing and progressive multiple sclerosis (RMS/PPMS). These BTKis, administered orally, possess the advantage of easy dosing while leveraging their […]
Survey finds neurologists seek to minimize side effects of treatment in Parkinson’s
Fewer than half of those dealing with Parkinson’s disease in the United States are able to gain clinical control of symptoms without experiencing side effects, according to results of a new study. Spherix Global engaged its initial Insights’ Market Dynamix to canvas more than 100 neurologists, employing a combination of quantitative survey and qualitative interview […]
US Neurologists Emphasize Tremendous Unmet Treatment Need in Parkinson’s Disease, According to Spherix Global Insights
Gene therapies and LRRK2 inhibition are at the forefront of prescribers’ interest, highlighting the need for a truly disease modifying therapy. [Exton PA, November 7, 2023] — Parkinson’s disease (PD) is the second-most prevalent neurodegenerative disorder following Alzheimer’s disease, affecting an estimated one million individuals in the United States1. With a significant absence of a […]
Pfizer and AbbVie oral migraine drugs earn top spots with physicians, survey finds
Oral drugs have raced to the front of the pack in the crowded migraine therapy space and appear to be staying put with physicians. Primary care physicians in particular are prescribing Pfizer’s Nurtec and AbbVie’s Ubrelvy and Qulipta, according to Spherix Global Insights’ latest quarterly survey of migraine drug prescribers. Primary docs reported more than […]
Another Medicine to Stop Migraine in its Tracks – Zavzpret™ is Now Available, but Where will Neurologists use it?
Will Pfizer’s marketing power help Zavzpret™ rapidly gain share in the crowded migraine market? Exton, PA., August 17, 2023 –In February 2023, Pfizer published their positive Phase 3 clinical trial results for zavegepant (new brand name, Zavzpret™). At the time, neurologists surveyed in a Spherix Global Insights study were “cautiously optimistic” that the first-ever, CGRP receptor […]
